Navigate
X
    QualityStocks
  • 18 years ago

Allos Therapeutics, Inc. (NASDAQ: ALTH)

Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company, is committed to developing and commercializing innovative small molecule drugs for the treatment of cancer. Pralatrexate (PDX), the Company’s lead product candidate, is a novel antifolate currently in a pivotal Phase 2 (PROPEL) trial. RH1, a targeted chemotherapeutic agent, is Allos Therapeutics’ other product candidate and is currently being evaluated in a Phase 1 trial. For further information, visit the Company’s web site at www.allos.com.

Tags Rodman & Renshaw
Related Post
  1. Quantum BioPharma Ltd. (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments

    In the United States alone, close to one million people are living with MS, with…

  2. Why Verbal Skills Aren’t Enough: WRAP’s New Doctrine Aims to Give Officers a Lawful Next Step

    California's SB 230 requires agencies to incorporate de-escalation and alternatives to force into their use-of-force…

  3. Beeline Holdings Inc. (NASDAQ: BLNE) Partners with Loft 100 Studios to Examine the Mortgage Market and New Approaches to Homeownership

    The partnership will focus on the production of a 45-minute “Bizumentary” examining current challenges and…